Oculis Holding Ag (OCS)
$16.34
+2.31
(+16.46%)▲
Live
Performance
- $14.50$16.47$16.34
11.26%
Downside
Day's Volatility :11.96%
Upside
0.79%
- $9.05$16.34$16.34
44.61%
Downside
52 Weeks Volatility :44.61%
Upside
0.0%
Returns
| Period | Oculis Holding Ag | Index (Russel 2000) |
|---|---|---|
3 Months | 20.12% | 0.0% |
6 Months | 17.41% | 0.0% |
1 Year | 43.02% | 0.0% |
3 Years | 28.83% | -23.0% |
Highlights
Market Capitalization | 591.5M |
Book Value | $2.70 |
Earnings Per Share (EPS) | -1.62 |
Wall Street Target Price | 28.64 |
Profit Margin | 0.0% |
Operating Margin TTM | -9177.55% |
Return On Assets TTM | -28.77% |
Return On Equity TTM | -58.12% |
Revenue TTM | 871.0K |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | -2.0% |
Gross Profit TTM | -21.3M |
EBITDA | -62.8M |
Diluted Eps TTM | -1.62 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.22 |
EPS Estimate Next Year | -2.3 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Next Quarter | -0.5 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 75.28%
Technicals Summary
Sell
Neutral
Buy
Oculis Holding Ag is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Oculis Holding Ag | 17.41% | 17.41% | 43.02% | 28.83% | 28.83% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Oculis Holding Ag | 62.68 | NA | NA | -2.22 | -0.58 | -0.29 | NA | 2.7 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Oculis Holding Ag | Buy | $591.5M | 28.83% | 62.68 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Oculis Holding Ag
Increasing Revenue
Revenue is up for the last 3 quarters, 185.0K → 245.0K (in $), with an average increase of 13.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -12.49M → -20.83M (in $), with an average decrease of 29.1% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 36.9%
Company Information
Organization | Oculis Holding Ag |
Employees | 36 |
CEO | Dr. Riad Sherif M.B.A., M.D. |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$16.34
+16.46%
Invesco Bulletshares 2025 Hi
$16.34
+16.46%
Schwab International Dividend Equity Etf
$16.34
+16.46%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$16.34
+16.46%
Lightpath Technologies Inc
$16.34
+16.46%
Vaneck Vectors Global Alternative Energy Etf
$16.34
+16.46%
First Trust Flexible Municipal High Income Etf
$16.34
+16.46%
Drx Dly Reg Bank Bull 3x
$16.34
+16.46%
Graniteshares 2x Long Pltr Daily Etf
$16.34
+16.46%